期刊文献+

益比奥联合左旋卡尼汀对透析患者贫血和临床症状的影响 被引量:8

下载PDF
导出
摘要 慢性肾衰竭是肾功能慢性损伤的终末阶段,贫血是其常见的并发症[1],维持性血液透析(maintenance hemodialysis,MHD)是慢性肾衰竭首选的临床治疗手段,但长时间的血液透析会导致机体内环境紊乱,红细胞脆性增加,寿命减少,加重患者贫血的症状,并且会产生低血压、肌肉痉挛、心律失常等一些列透析并发症[2,3].重组人促红细胞生成素(recombinant human erythropoietin,rhEPO)是其目前治疗CKD贫血最主要的手段,但MHD患者中常常会产生对rhEPO抵抗或者反应低的表现[4],因此本研究在国产促红素益比奥的基础上联合左旋卡尼汀,观察其对MHD患者贫血和临床症状的影响,以期为MHD贫血的临床治疗积累更多的循证医学证据.
出处 《中国中西医结合肾病杂志》 2015年第1期63-64,共2页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献9

  • 1Winkelmayer WC, Mitani AA, Goldstein BA, et al. Trends in ane- mia care in older patients approaching end - stage renal disease in the United States (1995 -2010). JAMA Intern Med,2014, 174(5) :699 -707.
  • 2张吉胜,尤晓青,刘婷,刘苑萍,高文波,包蓓艳.静脉与口服铁剂比较对维持性血透患者肾性贫血的临床疗效[J].中国临床药理学杂志,2010,26(2):93-95. 被引量:9
  • 3董睿,郭志勇,谌卫.血液透析及腹膜透析患者生活质量评价及相关因素分析[J].中国中西医结合肾病杂志,2010,11(7):606-610. 被引量:61
  • 4Ricci Z, Ronco C. Renal replacement therapy in the critically ill: getting it right. Curr Opin Crit Care,2012,18 ( 6 ) :607 - 612.
  • 5Al Saran K, Sabry A, Hassan AH. Effect of relative hypoparathy- roidism on the responsiveness to recombinant human erythropoie- tin in chronic hemodialysis patients:a single Saudi center experi- ence. Saudi J Kidney Dis Transpl,2013,24(4) :825 - 831.
  • 6Beiraghdar F, Panahi Y, Einollahi B, et al. Investigation of the ef- ficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis:a multi - center clinical trial. Clin Lab, 2012,58 ( 7 - 8 ) : 737 - 745.
  • 7杜继东.左卡尼汀的临床应用现状[J].天津药学,2013,25(3):54-58. 被引量:14
  • 8Jafari A, Dashti - Khavidaki S, Khalili H, et al. Potential nephro- protective effects of 1 - carnitine against drug - induced nephrop- athy : a review of literature. Expert Opin Drug Saf, 2013,12 ( 4 ) : 523 - 543.
  • 9宋洁,李小萍,张晓东,张建荣,李辉.左卡尼汀对血液透析患者促红细胞生成素所需剂量及微炎症状态的影响[J].第二军医大学学报,2013,34(2):219-222. 被引量:16

二级参考文献56

  • 1陈江华,何强,徐莹.维持性血液透析患者微炎症状态的认识与防治[J].中华肾脏病杂志,2005,21(2):117-118. 被引量:146
  • 2李丽疆,潘丽,庞建伟.左卡尼汀用于改善糖尿病足局部营养及代谢状况的临床观察[J].黑龙江医药科学,2006,29(3):31-32. 被引量:8
  • 3Parker PA,Izard MW, Maher JF. Thcraphy of iron deficiency ane mia in paitient on maintenance dialysis [ J ]. Nephron, 1983 ;23 : 229 - 231.
  • 4National Kidney Foundation. K/DOQI clinical pratice guidelines for anemia of chronic kidney disease [ J ]. Am J Kidney Dis, 2001 ; 37 (Suppl. 1 ) :S182 - S238.
  • 5Hays RD,Kallich JD,Mapes DL,et al.Kidney Disease Quality of Life Short Form(KDQOL-SFTM),Version l.3:A Manual for Use and Scoming.Santa Monica CA:RAND Corporation,1995.
  • 6Ware J.Gandek B.Overview of SF-36 health survey and the international quality of life assessment(IQDLA)project.J Clin Epidemiol,1998,51(11):903-912.
  • 7Bullinger M,Alonso J,Apolone G,et al.Translating health status questionnaires and evaluating their quality:the IQOLA project approach.International Quality of Life Assessment.J Clin Epidemiol,1998,51(11):913-923.
  • 8Carmichael P,Popoola J,John I,et al.Assessment of quality of life in a single centre dialysis population using the KDQOL-SF questionnaire.Qual Life Res,2000,9(2):195-205.
  • 9London GM,Marty C,Marchais SJ,et al.Arterial calcifications and bone histomorphometry in end stage renal disease.JAm Soc Nephrol,2004,15(7):1943-1951.
  • 10Ohri-Vachaspati P,Schgel AR.Quality of life implications of inadequate protein nutrition among hernodialysis patients.J RenNutr,1999,9(1):9-13.

共引文献96

同被引文献53

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部